Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation

Embed Size (px)

Text of Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against...


    Recurrence of Hepatitis B Is Associated WithCumulative Corticosteroid Dose andChemotherapy Against HepatocellularCarcinoma Recurrence After LiverTransplantationNam-Joon Yi,1 Kyung-Suk Suh,1 Jai Young Cho,1 Choon Hyuck Kwon,2 Kwang-Woong Lee,2

    Jae Won Joh,2 Suk-Koo Lee,2 Soon Il Kim,3 and Kuhn Uk Lee11Department of Surgery, Seoul National University College of Medicine; 2Department of Surgery, SamsungMedical Center, Sungkyunkwan University, School of Medicine; and 3Department of Surgery, YonseiUniversity College of Medicine, Seoul, Korea

    The incidence of hepatitis B (HB) recurrence after a liver transplantation has been reduced by prophylaxis with hepatitis Bimmunoglobulin (HBIG) and lamivudine. However, the long-term incidence of recurrence is 10%, and the factors associatedwith HB recurrence are unclear. This study analyzed the factors associated with HB recurrence in 203 recipients whounderwent liver transplantation for HB in 3 major centers in Korea over 4 years. Eighty-ve patients (41.9%) had ahepatocellular carcinoma (HCC). Preoperative active virus replicators with the HBeAg() (46.8%) and/or hepatitis B virusDNA() (39.4%) were observed in 136 patients (67.0%). The HB prophylaxis consisted of either HBIG monotherapy (n 95,HBIG group) or combination therapy with lamivudine (n 108, combination group). HB recurrence was dened as theappearance of the HBsAg. The follow-up period was 28.3 13.1 months (mean SD). HB recurred in 21 patients (10.3%)after transplantation. The time from transplantation to recurrence was 16.3 9.4 months. Pre-LT DNA positivity was moreprevalent in HBIG group (55.8%) than in the combination group (39.8%) (P 0.015). However, the incidence of HB recurrencewas similar in the HBIG (6.3%) and combination group (13.8%), as well as between the active replicators (12.5%) andnonreplicators (4.1%) (P 0.05). There was a far higher incidence of HB recurrence in patients receiving corticosteroid pulsetherapy (21.0% vs. 7.9%), patients who experienced HCC recurrence (31.3% vs. 8.6%), and patients receiving chemotherapyto prevent HCC recurrence (25.0% vs. 4.4%) (P 0.05). The cumulative corticosteroid dose was higher in patients whoexperienced recurrence of HB (P 0.002). Multivariable analysis conrmed the effect of the cumulative corticosteroid doseand chemotherapy to be risk factors. Liver transplantation for HB is safe, with low recurrence rates if adequate prophylaxis isused. However, the cumulative corticosteroid dose and the chemotherapy used for HCC were risk factors for HB recurrence,so careful monitoring for HB recurrence is needed in these patients. Liver Transpl 13:451-458, 2007. 2007 AASLD.

    Received December 19, 2005; accepted October 18, 2006.

    The outcome of liver transplantation (LT) for hepatitis Bvirus (HBV)-related liver diseases was dismal before theadvent of an effective means for preventing the virtuallyuniversal reinfection of the graft. Reinfection was fol-lowed by progressive destruction by recurrent hepati-

    tis. This led to quick graft failure. HBV-related liverdisease was once considered to be a contraindicationfor LT. However, over the last 15 years, there have beenmajor advances in the management of transplant can-didates with hepatitis B (HB). The long-term use of

    Abbreviations: ACR, acute cellular rejection; anti-HBc, hepatitis B core antibody; HB, hepatitis B; HBeAg, hepatitis B e antigen; HBIG,hepatitis B immunoglobulin; HBsAg, hepatitis B s antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LFT, liver functiontest; LT, liver transplantation.Address reprint requests to Kyung-Suk Suh MD, PhD, Department of Surgery, Seoul National University College of Medicine, 28 Yongon-Dong,Chongno-Gu, Seoul, Korea 110-744. Telephone: 82-2-2072-3789; FAX: 82-2-766-3975; E-mail: 10.1002/lt.21043Published online in Wiley InterScience (

    LIVER TRANSPLANTATION 13:451-458, 2007

    2007 American Association for the Study of Liver Diseases.

  • hepatitis B immunoglobulin (HBIG) therapy and theintroduction of new antiviral agents, such as lamivu-dine, against HBV infections have been major break-throughs.1,2 Today, the results of LT for HBV-relatedliver disease are similar to that of patients receivingtransplants for other indications. Nevertheless, 10% ofLT patients with underlying HB experience a recur-rence.3-5 The factors associated with HB recurrence areunclear.

    This study examined 203 patients who underwent LTfor HBV-related liver disease in 3 major centers in Ko-rea, with the aim of evaluating the risk factors associ-ated with HB recurrence and the safety of the HB pro-phylactic protocol after LT in the era of HBIG andlamivudine.


    Between January 1999 and December 2002, a total of203 adult patients (age 18 years or older) who under-went LT for HBV-related liver disease and were followedup for at least 6 months were enrolled onto this study.The mean interval between registration to the KoreanNetwork for Organ Sharing and the transplantation was5.4 7.9 months (mean SD, range, 0-64.4 months).

    Table 1 summarizes the patients data at the time oftransplantation. There were 151 cases of living donorLT and 56 cases of deceased donor LT, including 4cases of retransplantation. A hepatitis C virus coinfec-tion was found in 3 cases (1.5%). Eighty-ve patients(41.9%) were associated with a hepatocellular carci-noma (HCC). A replicative HBV infection was dened asthe presence of the hepatitis e antigen (HBeAg) and/orHBV DNA in serum. The HBV DNA was tested by means

    of a nonamplied hybrid capture assay with abranched-chain DNA assay (Greencross, Korea). Thedetection threshold for the DNA was 105 copies/mL.One hundred thirty-six patients (67.0%) were pre-LTactive replicators at the time of the transplantation.HBeAg positivity and HBV DNA positivity was noted in95 (46.8%) and 80 patients (39.4%), respectively. Therewere 92 patients (45.3%) whose donor tested positive toserum antibody against the hepatitis B core antigen(anti-HBc). There were 2 cases (1.0%) of fulminant hep-atitis B.

    Pretransplantation lamivudine therapy for active rep-licators was not a routine protocol. Pretransplantationlamivudine therapy was initiated in 55 patients(27.1%). Forty (30.3%) of 136 pre-LT active replicatorsunderwent pretransplantation lamivudine therapy.Overall, the mean duration of pretransplantation lami-vudine therapy was 2.1 5.3 months (range, 0.5-27.5months). There were 2 patients with breakthrough in-fection, but no patients underwent pretransplantationadefovir therapy.

    The prophylactic infusion of human HBV-specichepatitis B immunoglobulin (HBIG, antihepatitis Bimmunoglobulin, Greencross, Korea) was administeredintravenously to all patients after LT (Fig. 1). HBIG wasinitiated at the time of transplantation and was contin-ued indenitely. HBIG was administered at 10,000-20,000 IU during the anhepatic phase and 10,000 IUdaily for 7 days, followed by 10,000 IU weekly for therst month. Thereafter, the HBIG load was measured inorder to maintain the anti-HBs titers at 350 IU/L forcombination therapy with lamivudine, or the HBIGdose was xed at 10,000 IU for HBIG monotherapyevery month for the rst year. After then, the HBIG dose

    TABLE 1. Clinical Features of 203 Hepatitis B VirusRelated Liver Disease Patients at Time of Transplantation

    According to Posttransplantation Prophylactic Regimen



    (n 203)

    HBIG group

    (n 95)

    Combination group

    (n 108) P value

    Gender (male: female) 162:41 80:15 82:26 0.163Mean age (yr) (mean SD) 46.9 8.0 46.6 7.5 47.3 8.4 0.690Active replicator* 136 (67.0%) 63 (66.3%) 73 (67.6%) 1.000HBeAg positivity 95 (46.8%) 39 (41.1%) 56 (51.9%) 0.253HBV DNA

    Positivity 80 (39.4%) 53 (55.8%) 43 (390.8%) 0.015Titer (pg/dL) (mean SD) 215.5 674.6 348.1 898.2 610.3 1,080.8 0.007

    Donor anti-HBc positivity 92 (45.3%) 42 (44.2%) 50 (47.6%) 0.424HCV coinfection 3 (1.5%) 2 (2.1%) 1 (0.9%) 0.600HCC 85 (41.9%) 46 (48.4%) 39 (36.1%) 0.088UNOS status 0.532

    1 2 (1.0%) 0 2 (10.9%)2A 49 (24.1%) 24 (25.3%) 25 (230.0%)2B 114 (56.2%) 60 (63.1%) 74 (680.5%)

    Pre-LT lamivudine therapy 55 (27.1%) 29 (31.2%) 26 (24.3%) 0.071Duration (months) (mean SD) 7.6 7.8 9.7 7.9 50.5 70.4 0.189

    Abbreviations: HBIG, hepatitis B immunoglobulin; HBeAg, HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCV,hepatitis C virus; HCC hepatocellular carcinoma; UNOS, United Network for Organ Sharing; LT, liver transplantation.*HBeAg and/or HBV DNA positive recipients.

    452 YI ET AL.

    LIVER TRANSPLANTATION.DOI 10.1002/lt. Published on behalf of the American Association for the Study of Liver Diseases

  • was reduced every 4-8 weeks in order to maintain theanti-HBs titers at 200 to 250 IU/L, and lamivudinewas discontinued in combination therapy.

    Ninety-ve patients (46.8%) did not receive lamivu-dine and were treated with HBIG only after the livertransplantation (HBIG monotherapy, HBIG group). Onehundred eight patients (53.2%) were treated with lami-vudine combined with HBIG after the liver transplanta-tion (HBIG and lamivudine combination therapy, com-bination group) at a daily dose of 25-100 mg accordingto renal function. The prophylactic regimen was deter-mined according to guideline of the each center; Sam-sung Medical Center used HBIG monotherapy, and theother centers used combination therapy. Adefovir wasnot provided as a primary treatment after transplanta-tion in this study. Both the HBIG and combinationgroups were comparable with regard to the pre-LT clin-ical features (Table 1). However, the HBV DNA positivityand titer were much different. HBV DNA positivity wasmore frequent in the HBIG group (55.8%) than in thecombination group (39.8%) (P 0.015). HBV DNA titerwas higher in the HBIG group (